Results 41 to 50 of about 111,189 (247)

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

PRIORITY Study: Baseline and Post-Rituximab Immune Profiles in a Pediatric Cohort

Journal of Human Immunity
BackgroundPediatric utilization of rituximab encompasses autoimmune, renal, hematologic, and neurologic conditions. Its association with secondary hypogammaglobulinemia and unmasking of inborn errors of immunity is well recognized.
Dr. Jenny Garkaby, Dr. Andrew Wong-Pack, Dr. Leena Ahmed, Dr. Tania Cellucci, Dr. Dua Meghna, Dr. Rahul Chanchlani, Zaina Khan, Zaeem Nadeem   +7 more
doaj   +1 more source

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab

BMC Nephrology, 2020
Background Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving perioperative treatment with rituximab, which is associated with ...
Young Hoon Kim, Jee Yeon Kim, Dong Hyun Kim, Youngmin Ko, Ji Yoon Choi, Sung Shin, Joo Hee Jung, Su-Kil Park, Sung-Han Kim, Hyunwook Kwon, Duck Jong Han   +10 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies

Kidney International Reports
Introduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur.
Maxime Teisseyre, Marco Allinovi, Vincent Audard, Marion Cremoni, Giulia Belvederi, Alexandre Karamé, Matteo Accinno, Julien Duquesne, Vinod Sharma, Céline Fernandez, Kévin Zorzi, Mounir El Maï, Vesna Brglez, Sylvia Benzaken, Vincent L.M. Esnault, Alessandra Vultaggio, Harbir Singh Kohli, Raja Ramachandran, Calogero Lino Cirami, Barbara Seitz-Polski   +19 more
doaj   +1 more source

Rituximab in Minimal Change Disease

Canadian Journal of Kidney Health and Disease, 2017
Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal
Nima Madanchi, Martin Bitzan, Tomoko Takano   +2 more
doaj   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Risk Factors for Persistent Hypogammaglobulinemia in Pediatric and Young Adult Patients Receiving Rituximab

Journal of Human Immunity
RationaleRituximab is an anti-CD20 monoclonal antibody that can cause persistent hypogammaglobulinemia (PH) in 20–45% of patients, depending on the patient population. Risk factors for PH in pediatric patients following rituximab have been inconsistently
Kevin Ackerman, Nathaniel Srikureja, Jennifer Heimall, Di Sun   +3 more
doaj   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source

Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data

BMC Rheumatology
Background Rituximab is known as an efficacious drug for the treatment of Rheumatoid Arthritis (RA). The original administration schedule consisted of two infusions of 1000 mg with a 2-week interval.
Delphine Bertrand, Elias De Meyst, Michaël Doumen, Diederik De Cock, Johan Joly, Barbara Neerinckx, Sofia Pazmino, Nele Pype, Tom Conings, René Westhovens, Patrick Verschueren   +10 more
doaj   +1 more source